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Salivary gland tumors are rare, comprising less than
3% of all neoplasms of the head and neck region. The
majority of salivary tumors are located in the parotid
gland (70%), followed by the minor salivary glands
(22%) and the submandibular glands (8%) [1]. Onco-
cytic tumors comprise only 1% of all salivary gland
tumors [2]. Oncocytic carcinomas are even more un-
common, representing 11% of all oncocytic salivary
gland neoplasms, 0.5% of all epithelial salivary gland
malignancies and 0.18% of all epithelial salivary gland
tumors [3]. Oncocytic carcinoma arising in the salivary
glands, first described by Bauer and Bauer in 1953, 
is a rare, predominantly oncocytic neoplasm [3,4].
Moreover, oncocytic carcinoma arising in the sub-
mandibular gland is an extremely rare tumor and
only 11 cases have been reported to date [5]. We report a
51-year-old man with a previously benign oncocytoma
in his submandibular gland that transformed from 
a benign morphology to malignant cellular atypia
and mitosis. We performed immunohistochemical
staining with antibodies against Ki-67 to qualify
mitosis separately for clarity of the tumor. This study 
was approved by our Institutional Review Board
(IRB 09801-008).
CASE PRESENTATION
A 51-year-old man presented with a recurrent mass
in his left submandibular gland in August, 2008, and
a prior diagnosis of benign oncocytoma in the same
location. In February, 2005, he underwent total tumor
ablation for the benign oncocytoma in his left sub-
mandibular gland. Pathological examination of the
resected tissue of the earlier specimen revealed an
encapsulated tumor (Figure 1A) composed of uniform
oncocytes with fine chromatin and indistinct nucleoli
(Figure 1B). Mitotic figures were rarely found.
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Oncocytic carcinoma arising in the submandibular gland is an extremely rare tumor and only 11
cases have been reported previously. We report on a 51-year-old man with a previously benign onco-
cytoma in the submandibular gland that transformed from a benign morphology to malignant cel-
lular atypia and mitosis. To our knowledge, the current report is the first published case of a
malignant transformation from benign oncocytoma to oncocytic carcinoma of the submandibular
gland. The proliferative activity of the tumor cells was evaluated immunohistochemically using
antibodies against Ki-67.
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At the current presentation, he had a painless
swollen mass in the previously resected area. This
lesion had been slowly growing for 4 months. On clin-
ical examination, the mass was about 3.0 × 2.5 cm in
size, hard, rubbery and fixed. A palpable cervical lym-
phadenopathy was also found. The facial nerve and
other cranial nerves functioned normally. Neck sonog-
raphy revealed one well defined heterogeneous mass
lesion in the left submandibular space, measuring
3.3 × 2.8 cm in size. Several lymph nodes surrounding
the tumor were swollen, with the largest one measur-
ing about 1.2 × 0.9 cm in size. Computed tomography
of the neck demonstrated one enlarged mass lesion
about 3.0 cm in diameter in the left submandibular
region (Figure 2A) and an enlarged lymph node, of
about 1.4cm in diameter, anterior to the submandibular
mass (Figure 2B). Because recurrence of the oncocy-
toma was suspected, radical tumor resection with
unilateral, modified neck dissection (levels I–III) was
performed in September 2008.
Microscopically, the resected tumor revealed infil-
trating growth and was composed of atypical onco-
cytes arranged in solid sheets. Marked nuclear atypia,
cellular polymorphism and mitoses were observed
(Figure 3A). Focal areas of necrosis were also found.
The tumor had invaded the surrounding tissue, includ-
ing the muscular tissue, perineural spaces and lym-
phatic vessels (Figure 3B). Three of the four lymph
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Figure 1. (A) The tumor was well encapsulated (hematoxylin and eosin; original magnification, 100×). (B) Uniform oncocytes with
abundant eosinophilic granular cytoplasm, fine chromatin, indistinct nucleoli and rare mitoses (hematoxylin and eosin; original 
magnification, 400×).
Figure 2. (A) Axial computed tomography revealed a mass with central necrosis in the left submandibular region (arrows). (B) One
enlarged lymph node was found anterior to the mass (arrow).
nodes contained tumor metastases. Therefore, the
diagnosis of oncocytic carcinoma was established.
We performed immunohistochemical stains with
antibodies against Ki-67 (MIB-1, DAKO) to evaluate
the proliferative activity of the earlier and current
tumors. The frequency of Ki-67-positive cells was
lower (< 1%) in the patient’s previous oncocytoma
(Figure 4A) than in the current oncocytic carcinoma
(15–30%) (Figure 4B). We assumed from these clinical
and immunohistochemical findings that this malig-
nant tumor had transformed from the previously
benign oncocytoma. The patient received postopera-
tive adjuvant radiotherapy in the left submandibular
tumor bed (total 66 Gy), left submental space and
ipsilateral neck (total 59.4 Gy). He had no evidence of
recurrence after 6 months of follow-up.
DISCUSSION
The German pathologist Hürthle was the first re-
searcher to describe oncocytes as components of nor-
mal canine thyroid glands in 1894 [6]. The term
oncocyte was only coined in 1931 by Hamperl to
describe cells within Warthin’s tumor with abundant
granular eosinophilic cytoplasm [7]. The predomi-
nant ultrastructural feature of oncocytes is marked
mitochondrial hyperplasia [8]. Oncocytes have since
been described in many human tissues, including the
salivary gland, lacrimal gland, ocular caruncle, para-
thyroid, thyroid, pituitary, esophagus, liver, pancreas,
kidneys, adrenals, testicles and ovaries [2–4,9,10].
The diagnostic criteria of oncocytic carcinoma are
as follows: (1) no encapsulation; (2) local invasion; 
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Figure 3. (A) Atypical oncocytes with marked nuclear pleomorphism and prominent nucleoli (hematoxylin and eosin; original magni-
fication, 400×). (B) Muscular and lymphatic invasion (hematoxylin and eosin; original magnification, 400×).
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Figure 4. (A) Ki-67 immunohistochemical stain of the patient’s previous benign oncocytoma showing rare Ki-67-positive cells (< 1%)
(original magnification, 400×). (B) Ki-67 immunohistochemical stain of the patient’s current tumor showing oncocytic carcinoma,
with a high frequency of Ki-67-positive cells of up to 30% (original magnification, 400×).
(3) cellular polymorphism with scattered mitosis; (4)
perineural, vascular or lymphatic invasion; (5) regional
lymph node metastases; and (6) distant metastases
[4,10]. Our patient’s tumor fulfilled all of these criteria,
except for distant metastases. To our knowledge, the
development of a secondary oncocytic carcinoma of
the submandibular gland from a preexisting benign
oncocytoma has not been reported previously.
The proliferative activity of the oncocytic tumor
cells was evaluated immunohistochemically with anti-
bodies against Ki-67 (MIB-1). Ki-67, a non-histone pro-
tein localized on the long arm of human chromosomes,
is abundantly expressed in proliferating cells, except
during the G0 period of the cell cycle [11–13]. In normal
salivary glands, Ki-67 is expressed in an extremely
small number of cells [12]. The high frequency of Ki-
67-positive cells is closely associated with the grade
and early recurrence of carcinoma in various subtypes
of salivary gland tumors, including adenoid cystic
carcinomas, mucoepidermoid carcinoma and acinic
cell carcinoma [11,13]. There was a higher frequency 
of Ki-67-positive cells in the oncocytic carcinoma of
our patient. The average frequency of Ki-67-positive
cells was very low (< 1%) in the patient’s previous
benign oncocytoma, whereas up to 30% of the cells 
in the current oncocytic carcinoma were positive for
Ki-67. The higher frequency of Ki-67-positive cells in
the oncocytic carcinoma reflects active cell prolife-
ration [11–14]. Ki-67 immunostaining is valuable to
distinguish a benign oncocytoma from a oncocytic
carcinoma [3,11,12–14].
The combination of total surgical resection of the
tumor with a safe margin and neck dissection is
widely accepted for treating oncocytic carcinoma [3].
Adjuvant radiotherapy is an effective method for im-
proving local control. However, the survival rates of
oncocytic carcinoma were not fully documented in
retrospective studies, such as the Dutch International
Cooperative study or the study by Laramore et al
[15–18]. Chemotherapy is often considered in symp-
tomatic patients. However, the response to chemo-
therapy does not predict survival, and the currently
available chemotherapeutic agents do not provide
sustained remission [19–21].
Previous reports showed that oncocytic carcinoma
commonly recurred locally with subsequent lymph
nodes metastases and the prognosis of most patients
was poor [4]. Goode and Corio reported that onco-
cytic carcinoma of the salivary glands of less than
2 cm in size had better prognoses than larger tumors
[22]. In addition, patients who underwent aggressive
initial surgical intervention had significantly better
prognoses than those treated conservatively [11]. Mean-
while, Nakada et al concluded that distant metastasis
appeared to be the most important prognostic feature
of oncocytic carcinoma [23].
To our knowledge, immunohistochemical trans-
formation from benign oncocytoma to oncocytic carci-
noma of the submandibular gland has never been
reported. Further investigation of the prognosis of
patients with oncocytic carcinoma of the submandibu-
lar gland is warranted as more cases are reported.
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下頷腺惡性嗜酸細胞瘤是一種極罕見的腫瘤，根據我們所能夠查到的文獻資料顯示，
截至目前為止只有十一例病例報告被文獻記載，而由下頷腺良性嗜酸細胞瘤轉變為惡
性嗜酸細胞瘤的病例，在世界上是從來沒有被發表過的。由於下頷腺惡性嗜酸細胞瘤
如此罕見，本報告提出一 51 歲男性，於 2005 年曾接受左側下頷腺良性嗜酸細胞瘤手
術切除，在 2008 年於左側下頷腺的相同位置發現另一個腫瘤，經手術切除後，透過
臨床及免疫組織化學染色技術 Ki-67 表現數目多寡，我們合理的認定此復發的腫瘤已
經由過去的良性嗜酸細胞瘤轉變為惡性，藉提出此一罕見病例以供討論，並於本報告
中將惡性嗜酸細胞瘤流行病學、診斷、治療與預後做一簡短的文獻回顧。
關鍵詞：良性嗜酸細胞瘤，Ki-67 免疫組織化學染色法，惡性轉變，惡性嗜酸細胞瘤，下頷腺
（高雄醫誌 2010;26:327–32）
